P2Y12 CRISPR/Cas9 KO Plasmid (h): sc-417999
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- P2Y12 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the P2Y12 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
P2Y12 CRISPR/Cas9 KO Plasmid (h) | sc-417999 | 20 µg | $397.00 |
Overview
P2RY12 encodes the purinergic receptor P2Y12, a Gi-coupled GPCR that senses extracellular ADP to suppress cAMP signaling and coordinate platelet activation, aggregation, and thrombus stabilization through downstream PI3K/AKT and integrin signaling. Beyond hemostasis, P2Y12 is a characteristic marker of homeostatic microglia and modulates chemotaxis, process motility, and neuroimmune surveillance in response to nucleotides. Altered P2RY12 activity or expression has been linked to abnormal platelet reactivity and to microglial state changes observed in neuroinflammatory and neurodegenerative contexts. These features make P2RY12 a useful target for dissecting nucleotide-driven signaling, cell–cell communication, and immune–vascular crosstalk.
P2Y12 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the P2RY12 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the P2RY12 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the P2RY12 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish P2Y12 protein expression.
This CRISPR knockout system enables efficient generation of P2RY12-deficient cell models for investigation of P2Y12 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting P2RY12 exon(s) critical for P2Y12 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple P2RY12 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by P2Y12 CRISPR/Cas9 KO Plasmid (h) and P2Y12 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the P2RY12 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by P2Y12 HDR Plasmid (h) and P2Y12 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by P2RY12 homology arms to support homology-directed repair at defined P2RY12 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.